Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma (NAMS) Other Non-Current Liabilities (2022 - 2024)

NewAmsterdam Pharma's Other Non-Current Liabilities history spans 3 years, with the latest figure at $18.8 million for Q3 2024.

  • For Q3 2024, Other Non-Current Liabilities changed N/A year-over-year to $18.8 million; the TTM value through Sep 2024 reached $18.8 million, changed N/A, while the annual FY2023 figure was $7.8 million, 3.54% up from the prior year.
  • Other Non-Current Liabilities for Q3 2024 was $18.8 million at NewAmsterdam Pharma, up from $13.4 million in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $18.8 million in Q3 2024 and bottomed at $7.5 million in Q4 2022.
  • The 3-year median for Other Non-Current Liabilities is $13.4 million (2024), against an average of $12.8 million.
  • The largest YoY upside for Other Non-Current Liabilities was 3.54% in 2023 against a maximum downside of 3.54% in 2023.
  • A 3-year view of Other Non-Current Liabilities shows it stood at $7.5 million in 2022, then increased by 3.54% to $7.8 million in 2023, then skyrocketed by 141.5% to $18.8 million in 2024.
  • Per Business Quant, the three most recent readings for NAMS's Other Non-Current Liabilities are $18.8 million (Q3 2024), $13.4 million (Q2 2024), and $16.5 million (Q1 2024).